Teva launches generic version of Letairis tablets in US
2 May 2019 -

Teva Pharmaceutical Industries Ltd (Teva) (TASE:TEVA) (NYSE:TEVA) announced on Wednesday the launch of a generic version of Letairis (ambrisentan) Tablets, 5 mg and 10 mg, in the US.

Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalisation for worsening PAH, as well as to improve exercise ability.

For all female patients, ambrisentan tablets are only available through a restricted programme called the Ambrisentan Risk Evaluation & Mitigation Strategy (REMS) due to the risk of foetal harm.

According to Teva, the launch of ambrisentan tablets in the US is an important addition to its growing generic portfolio of nearly 60 cardiovascular medicines.

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.

Teva Pharmaceutical Industries specialises in generic and specialty medicines.